Viewing nowPregabalin Capsule 25mg (Pregabalin)
Pregabalin 25mg
Hard capsule · Prescription medication
CTC Bio Co., Ltd.

MFDS item code 202003631 · Approved 2020.05.19 · Insurance code 669502660
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also effective as an adjunct for partial seizures in patients with epilepsy, regardless of whether secondary generalization is present. Additionally, it is applicable for the treatment of fibromyalgia, helping reduce pain in patients. It is used to improve symptoms of various nerve-related disorders.
This medicine is administered orally as pregabalin, in 2 divided doses per day, with or without food. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See ‘5. Patients with Renal Impairment’) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target dose of 600 mg/day. If the target daily dose is not tolerated, dose reduction may be considered. (See ‘4. Discontinuation of Treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula: Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) ≥60: Initial dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60: Initial dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30: Initial dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Initial dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: Initial dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: The supplemental dose refers to a dose administered as a single additional dose. 6. Patients with Hepatic Impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly Patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication can increase the risk of suicidal thoughts or behaviors, so patients experiencing symptoms of depression or mood changes during use must inform their healthcare provider immediately. Patients with hypersensitivity to this medication or specific genetic lactose metabolism disorders should not take it. Diabetic patients should be cautious as weight gain may require adjustments to diabetes medication dosages. If signs of angioedema occur, the medication should be discontinued immediately, and a healthcare provider should be consulted. Elderly patients may be at increased risk of falls due to dizziness or drowsiness, so special caution is advised during initial use. Visual disturbances or changes in vision may occur, and if symptoms persist, consideration should be given to discontinuing the medication. Withdrawal symptoms such as insomnia, headache, and anxiety may occur upon discontinuation, so abrupt cessation should be avoided. Patients with a history of substance abuse should be cautious as the risk of misuse may be higher with this medication. Patients with decreased renal function may require dosage adjustments. Patients with severe heart disease should use caution while taking this medication. When used in conjunction with other medications that have central nervous system depressant effects, there may be a risk of respiratory depression, so caution is necessary. Pregnant women should not take this medication during early pregnancy due to the risk of fetal malformations, and women of childbearing potential should use effective contraception. Lactating women are advised to discontinue breastfeeding or the medication since it can be transferred into breast milk. Activities like driving or operating machinery should be done only after verifying whether this medication causes dizziness or drowsiness. In cases of overdose, symptoms such as confusion, drowsiness, and seizures may occur, and treatments such as hemodialysis may be necessary. Keep out of reach of children, and avoid transferring to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. It is recommended to maintain a storage temperature between 15 and 30 degrees Celsius. Proper storage can help maintain the medication's effectiveness for a longer duration.
A hard capsule with a light yellow upper part and white lower part containing white powder.
30 capsules per bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 25mg
Hard capsule · Prescription medication
CTC Bio Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.